Vivos Therapeutics, Inc. (VVOS) Latest Company News

Oct 15, 2026, 12:51 UTC
Vivos Therapeutics issued 12,000 shares of Series C Convertible Preferred Stock valued at $12 million to SOD Sciences in exchange for 2,907,338 SOD common shares and a 50% interest in the Test and related intellectual property.
Oct 1, 2026, 10:19 UTC
Vivos Therapeutics, Inc. dismissed Baker Tilly US, LLP as its independent auditor and engaged Haynie & Company as its new independent auditor, effective September 29, 2026.
Sep 9, 2026, 13:57 UTC
Vivos Therapeutics entered into twelve exchange agreements with Streeterville Capital on August 31, 2026, exchanging $2.86 million of outstanding principal under its secured promissory note for 11.445 million shares of common stock at $0.25 per share.
Source:
- rttnews.com
Sep 8, 2026, 10:03 UTC
Vivos Therapeutics, Inc. entered into an Exchange Agreement with Streeterville Capital, LLC to exchange securities for $8,225,000 and $3,250,000 in total value.
Aug 14, 2026, 22:27 UTC
Vivos Therapeutics, Inc. held its Q2 2026 earnings call on August 14, 2026.
Source:
- seekingalpha.com
- zacks.com
Jul 7, 2026, 00:00 UTC
Vivos Therapeutics, Inc. entered into a securities purchase agreement for a PIPE offering of 3,608,496 units at $0.582 per unit, raising approximately $2.1 million, with each unit consisting of one share of Series A Convertible Preferred Stock and a five-year warrant.
Jun 22, 2026, 12:30 UTC
Vivos Therapeutics extended its strategic financing agreement with Streeterville Capital, extending the timeframe to August 31, 2026, and reaffirming conversion of up to $4.5 million of debt into common stock and perpetual preferred equity.
Jun 10, 2026, 13:03 UTC
Vivos Therapeutics entered into a collaboration agreement with South Palm Cardiovascular Associates to form AIM Florida, LLC, expanding sleep apnea and insomnia diagnosis and treatment for cardiovascular patients in Florida.
Jun 8, 2026, 00:00 UTC
Vivos Therapeutics entered into an exchange agreement with Streeterville Capital to convert up to $4.5 million of outstanding secured note principal into equity, with conditions including completing equity financings by June 15, 2026.

VVOS

Vivos Therapeutics issued 12,000 shares of Series C Convertible Preferred Stock valued at $12 million to SOD Sciences in exchange for 2,907,338 SOD common shares and a 50% interest in the Test and related intellectual property.

Vivos Therapeutics, Inc. dismissed Baker Tilly US, LLP as its independent auditor and engaged Haynie & Company as its new independent auditor, effective September 29, 2026.

Vivos Therapeutics entered into twelve exchange agreements with Streeterville Capital on August 31, 2026, exchanging $2.86 million of outstanding principal under its secured promissory note for 11.445 million shares of common stock at $0.25 per share.

Vivos Therapeutics, Inc. entered into an Exchange Agreement with Streeterville Capital, LLC to exchange securities for $8,225,000 and $3,250,000 in total value.

Vivos Therapeutics, Inc. held its Q2 2026 earnings call on August 14, 2026.

Vivos Therapeutics, Inc. entered into a securities purchase agreement for a PIPE offering of 3,608,496 units at $0.582 per unit, raising approximately $2.1 million, with each unit consisting of one share of Series A Convertible Preferred Stock and a five-year warrant.

Vivos Therapeutics extended its strategic financing agreement with Streeterville Capital, extending the timeframe to August 31, 2026, and reaffirming conversion of up to $4.5 million of debt into common stock and perpetual preferred equity.

Vivos Therapeutics entered into a collaboration agreement with South Palm Cardiovascular Associates to form AIM Florida, LLC, expanding sleep apnea and insomnia diagnosis and treatment for cardiovascular patients in Florida.

Vivos Therapeutics entered into an exchange agreement with Streeterville Capital to convert up to $4.5 million of outstanding secured note principal into equity, with conditions including completing equity financings by June 15, 2026.